pyrophosphate and 3-methyl-3-4-epoxybutyl-diphosphate

pyrophosphate has been researched along with 3-methyl-3-4-epoxybutyl-diphosphate* in 1 studies

Other Studies

1 other study(ies) available for pyrophosphate and 3-methyl-3-4-epoxybutyl-diphosphate

ArticleYear
Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
    Journal of immunology (Baltimore, Md. : 1950), 2005, Aug-01, Volume: 175, Issue:3

    Human Vgamma9Vdelta2 T cells recognize nonpeptidic Ags generated by the 1-deoxy-d-xylulose 5-phosphate (many eubacteria, algae, plants, and Apicomplexa) and mevalonate (eukaryotes, archaebacteria, and certain eubacteria) pathways of isoprenoid synthesis. The potent Vgamma9Vdelta2 T cell reactivity 1) against certain cancer cells or 2) induced by infectious agents indicates that therapeutic augmentations of Vgamma9Vdelta2 T cell activities may be clinically beneficial. The functional characteristics of Vgamma9Vdelta2 T cells from Macaca fascicularis (cynomolgus monkey) are very similar to those from Homo sapiens. We have found that the i.v. administration of nitrogen-containing bisphosphonate or pyrophosphomonoester drugs into cynomolgus monkeys combined with s.c. low-dose (6 x 10(5) U/animal) IL-2 induces a large pool of CD27+ and CD27- effector/memory T cells in the peripheral blood of treated animals. The administration of these drugs in the absence of IL-2 is substantially less effective, indicating the importance of additional exogenous costimuli. Shortly after the costimulatory IL-2 treatment, only gammadelta (but not alphabeta) T cells expressed the CD69 activation marker, indicating that Vgamma9Vdelta2 T lymphocytes are more responsive to low-dose IL-2 than alphabeta T cells. Up to 100-fold increases in the numbers of peripheral blood Vgamma9Vdelta2 T cells were observed in animals receiving the gammadelta stimulatory drug plus IL-2. Moreover, the expanded Vgamma9Vdelta2 T cells were potent Th1 effectors capable of releasing large amounts of IFN-gamma. These results may be relevant for designing novel (or modifying current) immunotherapeutic trials with nitrogen-containing bisphosphonate or pyrophosphomonoester drugs.

    Topics: 2,3-Diphosphoglycerate; Animals; Antigens; CD4-CD8 Ratio; Cell Differentiation; Cell Proliferation; Cells, Cultured; Diphosphates; Diphosphonates; Epoxy Compounds; Hemiterpenes; Immunologic Memory; Injections, Intravenous; Injections, Subcutaneous; Interferon-gamma; Interleukin-2; Macaca fascicularis; Organophosphorus Compounds; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Th1 Cells

2005